Biotech firms are vying to harness the potential of RNA interference. But will its impact be in finding new disease targets, or in RNA-based drugs? Julie Clayton investigates.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Dmy initiates masculinity by altering Gsdf/Sox9a2/Rspo1 expression in medaka (Oryzias latipes)
Scientific Reports Open Access 25 January 2016
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
Author information
Author notes
Julie Clayton is a science writer based in Bristol, UK.
- Julie Clayton
Rights and permissions
About this article
Cite this article
Clayton, J. The silent treatment. Nature 431, 599–601 (2004). https://doi.org/10.1038/431599a
Published:
Issue date:
DOI: https://doi.org/10.1038/431599a
This article is cited by
-
Dmy initiates masculinity by altering Gsdf/Sox9a2/Rspo1 expression in medaka (Oryzias latipes)
Scientific Reports (2016)
-
RNA interference and potential therapeutic applications of short interfering RNAs
Cancer Gene Therapy (2005)
-
Gene Therapy Progress and Prospects: Recent progress in transgene and RNAi expression cassettes
Gene Therapy (2005)
-
About the nature of RNA interference
Applied Microbiology and Biotechnology (2005)
-
Making protein interactions druggable: targeting PDZ domains
Nature Reviews Drug Discovery (2004)
